Kula Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

Kula Investments’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$655K	Buy	+6,740	New	+$699K	0.16%	235

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Kula Investments's BMRN Position: Q1 2023 in Review

Kula Investments opened a new position in BioMarin Pharmaceuticals (BMRN) in Q1 2023: 6,740 shares worth $655K. The stake represents 0.16% of the portfolio and ranks #235 among its holdings.

552 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

Kula Investments held 6,740 shares of BioMarin Pharmaceuticals worth $655K as of Q1 2023.
BioMarin Pharmaceuticals was a new Kula Investments position in Q1 2023.
BioMarin Pharmaceuticals made up 0.16% of Kula Investments's portfolio in Q1 2023, its #235 holding.
552 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on Kula Investments's 13F filing for Q1 2023, filed 15 May 2023.